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Mitochondrial disease—the ever-widening circleThe discovery, in the late 1980s, that mutations in mitochondrial
DNA are associated with speciﬁc human disease states opened up an
entirely new ﬁeld of biomedical science. At ﬁrst, such associations
were found uniquely in cases of the so-called mitochondrial
encephalomyopathies, syndromic disorders of muscle and the CNS,
already long believed to involve dysfunction of the mitochondrial
OXPHOS (oxidative phosphorylation) system. Indeed, biochemical
defects of OXPHOS had already been clearly demonstrated via
enzymological analysis of muscle biopsies from patients, even though
the direct causes remained hitherto mysterious. However, even from
those early days, there were strong hints that the clinical phenotypes
associated with mitochondrial dysfunction would turn out to be far
wider. The ﬁrst clear-cut case of a maternally transmitted disease (i.e.
one etiologically linked to mitochondrial genotype) was Leber's
Hereditary Optic Neuropathy (LHON), a disorder apparently without
muscle involvement, but whose precise pathophysiology even today
remains unclear.
Since that time, the spectrum both of clinical phenotypes and of
genetic causes of diseases associated with mitochondrial dysfunction
has expanded dramatically and continuously. Many types of degen-
erative disorder, including most of the common neurodegenerative
conditions, have been shown to have mitochondrial failure or
abnormalities as a primary or major component. Even cancer is now
understood to involve a metabolic reprogramming in which mito-
chondrial functions are crucial, in addition to the now well-
established role of mitochondria in the life-death decisions of cells.
The range of nuclear genes involved in these various disorders has
now expanded to include not only those required directly for
mitochondrial biogenesis and metabolism, but a range of more exotic
functions, including intracellular signalling, protein turnover, nuclear
transcription and metal ion homeostasis. As well as enabling a better
understanding of themolecular aspects of disease processes at the cell
and whole-organism level, the identiﬁcation of new disease-related
genes, proteins and pathways provides a plethora of potential new
drug targets.
In regard to the disorders transmitted in the mitochondrial DNA,
attention is turning towards the provision of more effective genetic
counselling and designing possible avenues for therapy. To enable
clinicians to predict and eventually prevent the risk of transmission,
basic knowledge needs to be obtained regarding the genetics and cell
biology of mtDNA inheritance, in particular the so-called genetic
bottleneckwhich accounts for the segregation of mtDNA in the female
germline. A key aspect of mitochondrial transmission genetics, whose
importance has only begun to be recognized rather recently, concerns
the highly dynamic nature of the mitochondria, which undergo
frequent ﬁssion, fusion and intracellular movement in virtually all
cell-types. Defects in the machinery of mitochondrial division have0925-4439/$ – see front matter © 2009 Published by Elsevier B.V.
doi:10.1016/j.bbadis.2009.11.001been shown to be primary causes of a number of diseases, including,
for example, the commonest type of dominantly inherited optic
atrophy. Since the mitochondrial division machinery can also
inﬂuence the distribution of different mtDNA molecules at cell
division, for example those bearing point mutations or genomic
rearrangements, it now needs to be considered as a component in the
etiology and progression of mtDNA diseases more generally. Hun-
tington's disease presents another example, where the major role of
the long-identiﬁed disease gene now appears to be in the trafﬁcking of
mitochondria in the extended network of cellular projections that
characterize neurons.
A major class of mitochondrial disorders is now understood to be
caused by defects in inter-genomic signalling, commonly attributable
to mutations in nuclear genes responsible for faithful maintenance of
mtDNA and assembly of its expression products. Many such cases are
manifested as so-called mtDNA depletion syndrome, in which the
copy number of mtDNA is drastically decreased in speciﬁc tissues. The
superﬁcially bewildering range of clinical features in speciﬁc cases is
now becoming understood to reﬂect a much greater tissue-speciﬁcity
of nucleotide metabolism and transport than hitherto expected.
Even if we conﬁne ourselves to those conditions directly
associated with dysfunction of the OXPHOS system, mitochondrial
disease is not simply a case of ATP insufﬁciency. Although ATP
production is the principal output of OXPHOS, in different cell-types
the generation of respiratory energy is directed at (and sometimes
regulated by) other physiological processes, such as the maintenance
of redox homeostasis, the intracellular ﬂux of calcium and other ions,
and a range of biosynthetic pathways. To understand mitochondrial
disease and its physiological manifestations requires us to determine
how these various functions are interlinked. Furthermore, the
phenotypic spectrum of mitochondrial disease is determined, in
part, by the evolutionary origins of mitochondria as endosymbiotic
organelles, and the various functions that have either been preserved
from the prokaryotic ancestor of mitochondria or newly evolved to
facilitate the endosymbiotic process.
The prospects for therapy of mitochondrial disorders remain
comparatively poor. This is due, in part, to the centrality of
mitochondrial pathways in the life of every cell, as well as to the
inherent difﬁculties in manipulating mtDNA. However, some novel
ideas for genetic therapy have recently appeared on the horizon.
Whilst thesewill undoubtedly takemany years to develop to the point
where they could be applied clinically, they will at least give tangible
hope to mitochondrial disease sufferers and their families.
In this special section of BBA—Molecular Basis of Disease a
distinguished panel of expert scientists present their current outlook
on mitochondrial disease, covering the various topics outlined above.
Whilst progress is always slower than onemight hope, we believe that
1096 Prefacethe application of modern techniques in molecular biology will
resolve most of the outstanding questions about mitochondrial
disease in the coming decades. In addition, the growing co-operation
in the ﬁeld between clinical and basic scientists and between experts
in many countries opens the prospect of a rapid translation of
discovery into practical health beneﬁts.
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